CCR5-modified CD34+ cell (Peking University)

N/A

Report date: 2023/01/08 19:06:04

Base Information

Drug NameCCR5-modified CD34+ cell (Peking University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesPeking UniversityCapital Medical University
China Registration ClassN/A

Develop Information

Active CompaniesPeking UniversityCapital Medical University
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A